Demeter Lisa M, Bosch Ronald J, Coombs Robert W, Fiscus Susan, Bremer James, Johnson Victoria A, Erice Alejo, Jackson J Brooks, Spector Stephen A, Squires Kathleen M, Fischl Margaret A, Hughes Michael D, Hammer Scott M
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.
J Clin Microbiol. 2002 Jun;40(6):2089-94. doi: 10.1128/JCM.40.6.2089-2094.2002.
We determined the frequency with which human immunodeficiency virus (HIV) peripheral blood mononuclear cell cultures convert from positive to negative in subjects enrolled in a substudy of AIDS Clinical Trials Group (ACTG) 320, which compared the efficacy of treatment with a combination of indinavir, zidovudine, and lamivudine (indinavir arm) to that of a combination of zidovudine and lamivudine (dual-nucleoside arm). All subjects included for study had positive baseline HIV cultures. Cultures were performed in real time with 10(7) fresh patient peripheral blood mononuclear cells, using the ACTG consensus method. We found lower rates of positive HIV cultures in the indinavir treatment arm than in the dual-nucleoside treatment arm (64 versus 96% at week 24, P < 0.001). Within the indinavir arm of the study, we found that positive cultures were less likely to occur in samples with a plasma HIV type 1 (HIV-1) RNA level of <500 copies/ml than in those with a level of >or=500 copies/ml (44 versus 90%, P < 0.001). In addition, HIV cultures from samples with HIV-1 RNA levels of >or=500 copies/ml turned positive 8.5 days earlier, on average, than those from samples with levels of <500 copies/ml (P < 0.001). However, 38% of samples with plasma RNA levels of <50 copies/ml still were positive for HIV by culture. Thus, the rates of HIV isolation by standard culture procedures decrease as the plasma viral load decreases below 1,000 copies/ml; however, HIV isolates were still obtained from a substantial proportion of subjects with RNA levels of <50 copies/ml. The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load.
我们确定了参与艾滋病临床试验组(ACTG)320一项子研究的受试者中,人类免疫缺陷病毒(HIV)外周血单核细胞培养物从阳性转为阴性的频率。该子研究比较了茚地那韦、齐多夫定和拉米夫定联合治疗(茚地那韦组)与齐多夫定和拉米夫定联合治疗(双核苷组)的疗效。所有纳入研究的受试者基线HIV培养均为阳性。采用ACTG共识方法,用10⁷新鲜患者外周血单核细胞实时进行培养。我们发现茚地那韦治疗组的HIV阳性培养率低于双核苷治疗组(第24周时分别为64%和96%,P<0.001)。在该研究的茚地那韦组中,我们发现血浆HIV-1 RNA水平<500拷贝/ml的样本中阳性培养的可能性低于水平≥500拷贝/ml的样本(分别为44%和90%,P<0.001)。此外,HIV-1 RNA水平≥500拷贝/ml的样本的HIV培养平均比水平<500拷贝/ml的样本早8.5天转为阳性(P<0.001)。然而,血浆RNA水平<50拷贝/ml的样本中有38%经培养仍为HIV阳性。因此,当血浆病毒载量降至1000拷贝/ml以下时,标准培养程序的HIV分离率会降低;然而,仍从相当比例的RNA水平<50拷贝/ml的受试者中获得了HIV分离株。在试图从血浆病毒载量受到抑制的患者中获取HIV分离株时,应考虑HIV培养转为阳性所需时间的延迟。